Saturday 17 October 2026
Export CNSP’s income statement to Excel — free account
CNS Pharmaceuticals, Inc.
CNSP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.1% and free cash flow grew 33.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.33
−6.37%
Follow CNSP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(197.12%) | (296.28%) | (298.64%) | (106.62%) | |
| (135.60%) | (182.99%) | (179.17%) | (91.64%) | ||
ROIC |
(17,934.92%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(138.53%) | (394.29%) | 3,418.98% | (91.75%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(29.03) | (31.24) | (22.56) | (1.97) | |
Free Cash Flow |
(16.23) | (13.84) | (15.25) | (13.45) | |
Capital Expenditures |
— | (0.03) | (0.03) | (0.03) | |
| Other line items | |||||
Cash ROIC |
(82.08%) | (118.03%) | (504.65%) | (35.21%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(874.18) | (1,051.75) | (1,100.93) | (1,120.21) | |
Operating CF/Net income |
1.24 | 0.87 | 0.92 | 0.80 | |
Depreciation/Fixed assets |
1.26 | 0.22 | 0.21 | 0.99 | |
Capex/Depreciation |
0.00 | (6.74) | (6.55) | (2.17) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(29.03) | (31.18) | (22.51) | (1.96) | |
Capex per Share |
0.00 | (0.06) | (0.05) | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates